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Patterns of herpes simplex virus shedding over
1 month and the impact of acyclovir and HIV in
HSV-2-seropositive women in Tanzania
Clare Tanton,1,2 Helen A Weiss,1 Jerome LeGoff,3 John Changalucha,2 Tim C Clayton,1
David A Ross,1 Laurent Belec,4 Richard J Hayes,1 Deborah Watson-Jones1,5
ABSTRACT
Objectives Few studies have examined the frequency
and duration of genital herpes simplex virus (HSV)
shedding in sub-Saharan Africa. This study describes
HSV shedding patterns among a sample of HSV-2-
seropositive women enrolled in a placebo-controlled trial
of HSV suppressive therapy (acyclovir 400 mg twice
a day) in Tanzania.
Methods Trial participants were invited to participate in
a substudy involving 12 clinic visits over 4 weeks. At
each visit, cervical, vaginal and external skin swabs were
taken and analysed for HSV DNA using inhouse real-time
PCR.
Results HSV shedding was mainly subclinical (90%; 57/
63 shedding days in the placebo arm). The most frequent
shedding site was the external skin, but HSV DNA was
detected from all three sites on 42% (27/63) of shedding
days. In HIV-negative women, HSV DNA was detected
on 3% (9/275) of days in the acyclovir versus 11% (33/
309) in the placebo arm, while in HIV-positive women,
detection was on 14% (23/160) versus 19% (30/155) of
days, respectively.
Conclusions HSV shedding was common, varying
greatly by individual. Shedding rates were similar to
studies in African and non-African settings. Among HIV-
negative women, shedding rates were lower in the
acyclovir arm; however, acyclovir did not substantially
impact on HSV shedding in HIV-positive women.
Herpes simplex virus (HSV) type 2, is the most
frequent cause of genital ulcer disease.1 Infection is
latent most of the time, but HSV reactivations,
either clinical or subclinical, occur throughout an
individual’s life.2 3 HSV shedding occurs more
frequently in HIV-positive individuals.4e6
There are few studies of HSV shedding in
sub-Saharan Africa. Some,5 7 but not all,8e11
suggest that shedding rates among women may be
higher than in developed countries, possibly due to
the presence of other co-factors such as sexually
transmitted infections (STI) or vaginal cleansing
practices. Bacterial vaginosis, highly prevalent in
women from sub-Saharan Africa, has been associ-
ated with increased vaginal HSV DNA shedding.12
The WHO recommends administering anti-
herpes therapy as part of syndromic management
in settings where herpes accounts for greater than
30% of genital ulcer disease,13 but recent rando-
mised controlled trials of the impact of this
strategy on ulcer healing have had mixed
results.14e16 A more detailed understanding of
HSV shedding patterns may help interpret these
ﬁndings and those of HSV suppressive therapy
trials reporting no impact on HIV acquisition or
transmission.17e19
In this study, we describe HSV shedding patterns
and the effect of acyclovir and HIV on shedding
over 1 month among a sample of HSV-2-seroposi-
tive women in Tanzania enrolled in a randomised
placebo-controlled trial of HSV suppressive
therapy.
METHODS
Study participants and procedures
This study was nested within a randomised
placebo-controlled trial of acyclovir 400 mg twice
a day conducted in 19 communities in northwestern
Tanzania (ISRCTN 35385041). Screening, random-
isation and follow-up procedures for this trial have
been described previously.17 The trial evaluated the
effect of HSV suppressive therapy on HIV incidence
in HIV-negative women and cervicovaginal HIV
shedding in HIV-positive women.17 20
This study was conducted between August and
October 2005 in two of the 19 trial communities,
with the communities chosen for logistical reasons.
Women were eligible if they were trial participants,
had not withdrawn from study tablets, were
healthy enough to participate, were not planning to
move within the follow-up period and were
attending their main trial 18-month follow-up visit
in these two communities. Trial counsellors gave
eligible women information about the substudy,
and those interested in participating were given an
enrolment appointment 2e6 weeks later.
Eligibility was re-assessed at the enrolment
appointment. Additional eligibility criteria were an
ability to understand the study and not planning to
travel for one period of more than 4 days or for two
periods of 3 days or more during the follow-up
period. Women were enrolled following written or
ﬁngerprint consent.
A short interview collected information
including current contraception and STI symp-
toms. A genital examination was performed, clin-
ical ﬁndings were noted and three genital swabs
were collected, one from each of the cervix and
vagina as previously described21 and one from the
external genitalia by rolling the swab over the
clitoris, vulva and perianal area. Swabs were stored
dry in separate tubes. An additional swab was
taken from any genital ulcers. STI were treated
syndromically according to Tanzanian national
guidelines. Women were offered condoms.
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To avoid unblinding the ﬁeld team to treatment allocation and
HIV status, enrolment was monitored by the independent trial
statistician who informed the team when sufﬁcient participants
had been enrolled, to give a minimum sample size of 15 women
in each of four strata, ie, HIV-positive women on acyclovir/
placebo and HIV-negative women on acyclovir/placebo.
Follow-up
Women attended the study clinic three times per week and were
followed for 4 weeks, for a maximum of 12 visits (including
enrolment). At each visit, a genital examination was carried out
and swabs were collected, as detailed above.
Laboratory analyses
Swabs were frozen at 208C immediately after collection and
placed in a 808C freezer within 2 weeks. Lysis buffer was added
to cervical, vaginal and external skin swabs before extraction to
protect the nucleic acids. Tubes containing the swabs and lysis
buffer were vortexed brieﬂy, incubated at 568C for 10 min and
then vortexed brieﬂy again. Swabs were transferred to the swab
extraction tube system (Roche Molecular Diagnostics, Meylan,
France) and centrifuged at 12 000 rpm for 1 min. Recuperated
ﬂuid was added to the original tube. Nucleic acid extraction was
carried out using the NucliSens EasyMag system (bioMérieux,
Marcy l’Etoile, France). HSV DNA was quantiﬁed using an
inhouse real-time PCR22 and the Applied Biosystems 7300 Real-
time PCR System (Applied Biosystems, Courtaboeuf, France).
Genital ulcer swabs were tested for Trephonema pallidum, HSV
and Haemophilus ducreyi using multiplex PCR.
Statistical methods
As the main aim of this study was descriptive, no formal sample
size calculation was carried out although it was intended to
include at least 15 women in each of the four study strata from
these two sites.
Data were double-entered and validated in dBase IV and
analysed using Stata 10.
The threshold of quantiﬁcation for HSV DNA was 110 copies
per swab. Shedding quantities below this threshold were classed
as undetectable. Viral load data were log10 transformed for
analysis.
The main analysis is based on the overall ‘shedding rate’ in
each strata, deﬁned as the total number of samples with HSV
detected divided by the total number of visits from which
samples were available (‘per visit’ analysis). This provides the
most consistent measure regardless of the number of swabs
collected.23 Additional analyses included ‘per woman’ analyses
in which the outcome is the percentage of visits when shedding
was detected for each woman grouped into the following cate-
gories: none, less than 25%, 25% to less than 50% and 50% to
less than 75%.
Shedding was deﬁned as clinical if it occurred on a day when
ulcers or blisters were observed by the clinician at any site and
subclinical if it occurred on a day when no ulcers or blisters were
observed.
The association of acyclovir with HSV shedding rate (‘per
visit’ analysis) was analysed with logistic regression using
generalised estimating equations with an exchangeable correla-
tion matrix, adjusting for within-woman clustering. Analysis of
the ‘per woman’ outcomes used ordinal logistic regression. The
per-visit analysis examines HSV shedding overall combining
data from all women. In the per-woman analysis, we examine
the persistence of HSV shedding from the perspective of an
individual participant.
Adherence was estimated within the main trial by tablet
count at each 3-month follow-up visit. Adherence for the
18e21-month follow-up period was used as an estimate for
adherence within this 1-month substudy.
The study protocol was approved by the London School of
Hygiene and Tropical Medicine ethics committee and the
Medical Research Coordinating Committee of Tanzania. Within
the main trial participants had access to voluntary counselling
and testing for HIV and HIV-positive women were referred to
the closest care and treatment centre for HIV.17 20
RESULTS
Cohort recruitment and follow-up
In total, 124 women were given information about the substudy
at their 18-month follow-up visit. Appointments were accepted
by 102 (82%), of whom 78 (76%) were enrolled. Participants had
12 scheduled visits, including enrolment, and 96% (899/936) of
potential visits were attended, with most women (n¼69; 88%)
completing all visits. Data were analysed from 77 women
attending two or more visits. Of these, 50 were HIV seronega-
tive (24 randomly assigned to acyclovir and 26 to placebo) and
27 were HIV seropositive (14 randomly assigned to acyclovir and
13 to placebo). Two women were taking antiretroviral therapy.
Study population characteristics
Substudy participants were slightly older than trial participants
not enrolled in the substudy (28.8 vs 27.3 years for HIV-negative
and 30.0 vs 27.9 years for HIV-positive women). There were
no other differences between these two groups including
a self-reported history of genital ulcers.
The median age was 29 years (IQR 26e33) and over 60% of
women were divorced, separated or widowed (table 1). A history
of genital ulcers or blisters was reported by 30% of participants.
Characteristics were broadly similar by both HIV status (table 1)
and treatment arm (data not shown).
Estimated adherence during the 3-month period in which this
study was nested was 90% or greater for 26/50 (52%) of HIV-
negative participants and 13/27 (48%) of HIV-positive partici-
pants. Overall, 24/38 (63%) substudy women in the acyclovir
arm had 90% or greater reported adherence compared with
15/39 (38%) in the placebo arm (p¼0.03).
Clinical symptoms and association with HSV shedding
During follow-up, in 26 HIV-negative women on placebo there
were three visits in which signs consistent with clinical HSV
were present, in three different women. Only two were associ-
ated with cervicovaginal or perineal HSV DNA detection; ulcer
swabs were not taken from either woman. One of the 13 HIV-
positive women on placebo had a clinical herpetic episode lasting
four visits, with HSV DNA detected at all visits. Ulcer swabs
were HSV positive at the ﬁrst three visits. There were no clinical
HSVepisodes in the 24 HIV-negative women on acyclovir and in
14 HIV-positive women on acyclovir, despite six visits (in two
women) when signs consistent with clinical HSV were present,
HSV DNA was detected on only one visit and from only one
ulcer swab.
Per-visit analysis of shedding
Overall, HSV DNA was detected at 63 visits (14%) in the
placebo arm; 33 visits (11%) in HIV-negative women and 30
visits (19%) among HIV-positive women. On most of these
visits (57/63; 90%), no clinical signs were seen (31/33; 94% in
HIV-negative and 26/30; 87% in HIV-positive women).
Shedding was most frequently detected from the external
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vulval/perineal/perianal skin (10% and 17% of visits in HIV-
negative and HIV-positive women, respectively).
A similar proportion of shedding days involved shedding from
all sites among HIV-negative (14/33; 42%) and HIV-positive
(13/30; 43%) women. Most single-site shedding days involved
the external skin (21/26; 81% overall).
Among HIV-negative women, HSV DNA was detected less
often in the acyclovir (3%) than in the placebo arm (11%; OR
0.28; 95% CI 0.12 to 0.66; table 2) and the proportion of shed-
ding days that were multisite was lower among women in the
acyclovir arm (1/9 (11%) vs 13/30 (42%); p¼0.08). Among HIV-
positive women, shedding rates were more similar in the two
arms (14% in the acyclovir arm; 19% in the placebo arm; OR
0.69; 95% CI 0.26 to 1.85; table 2). Similar reductions in shed-
ding were seen at each anatomical site (table 2), although
numbers were small.
Further analyses among HIV-negative participants stratiﬁed
by estimated adherence found weak evidence for a stronger
association between shedding and acyclovir therapy in those
with estimated adherence of 90% or greater over the 3-month
period (6/191 vs 22/120, OR 0.14; 95% CI 0.05 to 0.43)
compared with those with estimated adherence less than 90% or
unknown (3/84 vs 11/189, OR 0.61; 95% CI 0.18 to 2.09;
pinteraction¼0.085). There were too few women for a similar
analysis in HIV-positive women.
Per-woman analysis of HSV shedding
In the placebo arm, 13/26 (50%) of HIV-negative women and
9/13 (69%) of HIV-positive women had HSV DNA detected
from at least one swab during follow-up. Figure 1A shows
shedding patterns among these women. In HIV-negative and
HIV-positive women, 58% and 75% of shedding episodes,
respectively, lasted only one visit. Overall, 19% and 38% of
HIV-negative and HIV-positive women, respectively, had two or
more HSV shedding episodes during follow-up. Figure 1A illus-
trates the individual variability in HSV shedding. For example,
Table 1 Key characteristics of substudy participants, by HIV-1 status at enrolment*
Characteristic
HIV seronegative
(N[50) n (%)
HIV seropositive
(N[27) n (%)
All participants
(N[77) n (%)
Sociodemographic characteristics
Median age (IQR), years 29 (26e32) 30 (25e34) 29 (26e33)
Marital status
Single 6 (12) 4 (15) 10 (13)
Married/living as married 16 (32) 4 (15) 20 (26)
Divorced/separated 24 (48) 15 (56) 39 (51)
Widowed 4 (8) 4 (15) 8 (10)
Behavioural characteristics
Median age at first sex (IQR), years 16 (15e18) 16 (15e17) 16 (15e18)
Median no of lifetime partners (IQR),
years
4 (3e5) 6 (4e20) 5 (3e7)
No of times cleanses vagina per day
Does not cleanse 20 (40) 9 (33) 29 (38)
1e2 13 (26) 8 (30) 21 (27)
$3 17 (34) 10 (37) 27 (35)
Clinical characteristics
History of genital ulcers/blisters 17 (34) 6 (22) 23 (30)
Episode of GUD in past year 12 (24) 4 (15) 16 (21)
Using hormonal contraceptivey 23 (46) 17 (63) 40 (52)
Biological characteristics
Geometric mean plasma HIV RNA
loadz (IQR), copies/ml
e 42046 (7609, 169085)x e
Cervicovaginal HIV-1 RNA detectedz e 14 (58) e
*Variables collected at screening unless indicated.
yAt enrolment to the substudy.
zAt randomisation.
xExcluding three women who seroconverted between randomisation and enrolment to the substudy.
GUD, genital ulcer disease.
Table 2 Effect of aciclovir on overall and site specific shedding by HIV status
HIV negative HIV positive
Aciclovir n (%)
(N[275)
Placebo n (%)
(N[309) OR* (95% CI)
Aciclovir n (%)
(N[160)
Placebo n (%)
(N[155) OR* (95% CI)
No of (%) visits HSV DNA detected
Any swab 9 (3) 33 (11) 0.28 (0.12 to 0.66) 23 (14) 30 (19) 0.69 (0.26 to 1.85)
pinteraction (treatment and HIV status) ¼0.17
Cervical swabs 3 (1) 16 (5) 0.20 (0.05 to 0.82) 15 (9) 15 (10) 0.97 (0.29 to 3.23)
pinteraction¼0.09
Vaginal swabs 6 (2) 21 (7) 0.30 (0.10 to 0.95) 16 (10) 18 (12) 0.85 (0.25 to 2.88)
pinteraction¼0.22
Vulval/perineal/perianal swabs 3 (1) 31 (10) 0.10 (0.03 to 0.35) 17 (11) 26 (17) 0.59 (0.18 to 1.92)
pinteraction¼0.05
*OR for the effect of aciclovir on HSV DNA detection compared with placebo.
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participants 10 and 25 had protracted periods of subclinical HSV
shedding with high viral loads following similar trends at all
anatomical sites. In other women, for example, participants 16
and 60, viral shedding was short-lived, with low viral load at
only one site. In general, multisite shedding was associated with
higher mean viral loads (4.07 log vs 2.90 log; p<0.012).
In contrast, in the acyclovir arm, 8/34 (33%) of HIV-negative
women and 9/14 (64%) of HIV-positive women had HSV
detected from at least one swab during follow-up. Figure 2
shows the proportion of visits when HSV DNAwas detected by
HIV status and treatment arm. Among HIV-negative women,
those on acyclovir tended to have less frequent shedding than
those on placebo (OR 0.36; 95% CI 0.12 to 1.12). A similar trend
was seen in HIV-positive women but the CI is wider because
there were fewer women in the analysis (OR 0.60; 95% CI 0.15
to 2.40). In HIV-negative women on acyclovir, all shedding
episodes lasted only one visit (ﬁgure 1B) and only two out of
nine episodes involved shedding at more than one site. In
contrast, among HIV-positive women on acyclovir, shedding
patterns were similar to women on placebo.
DISCUSSION
In this study we describe site-speciﬁc genital HSV shedding over
1 month in a population of HSV-2-seropositive Tanzanian
women participating in a trial of HSV suppressive therapy with
acyclovir 400 mg twice a day. Overall, HSV shedding was
mainly subclinical. HSV was most commonly shed from the
external skin; however, in the placebo arm on 42% of days when
HSV DNA was detected, shedding was from all sites. Shedding
rates in HIV-negative women were 3% of days in women on
acyclovir compared with 11% in women on placebo (OR 0.28;
95% CI 0.12 to 0.66). For HIV-positive women, the rates were
14% in the acyclovir arm and 19% in the placebo arm (0.69; 95%
CI 0.26 to 1.85).
We found similar shedding rates to studies in the USA. In
HIV-negative women, in a study of valacyclovir to reduce HSV
transmission, HSV DNA was detected on 11.4% of days from
a swab collected from the cervicovaginal area, the vulva and the
perianal area24 and on 9% of days from clinician-collected
vaginal swabs in another study.12 Another US study, however,
reported an overall shedding rate of 27.9% from swabs taken
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Figure 1 Quantity of cervical, vaginal and perineal/perianal herpes simplex virus (HSV) DNA detected at each visit for each woman with at least one
visit with detectable HSV DNA. (A) Placebo arm and (B) acyclovir arm.
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from the cervicovaginal area (23%) and vulva (23%).25 One US
study in HIV-positive women found HSV DNA on 19.2% of
days from swabs taken from the vaginal-vulval and rectal area.26
Only two studies have reported longitudinal HSV shedding
rates in sub-Saharan Africa and show similar results to our
study.8 10 In 20 HIV-negative and 22 HIV-positive women in
Burkina Faso who attended weekly visits for 4 weeks, HSV DNA
was detected in cervicovaginal lavages on 9% and 21% of days,
respectively.8 A study of 17 HIV-positive women in Kenya
examined cervical HSV shedding rates over 1 month, and
detected HSV DNA on 10% of days.10 Occasionally, very high
prevalences of HSV shedding (22e43%) have been reported by
cross-sectional studies in sub-Saharan Africa.5 7
Among HIV-negative women, HSV shedding rates were lower
overall and from each anatomical site in the acyclovir arm
compared with the placebo arm. There was some evidence
(p¼0.085) for an interaction between acyclovir and adherence
among HIV-negative women, with a stronger effect being seen
in those with adherence of 90% or greater. This contrasts with
the trial ﬁndings,17 in which there was no evidence for an effect
of acyclovir on HSV DNA detection overall, although there was
a trend in good adherers. The substudy may have selected for
better adherers by enrolling women who were still taking study
tablets after 18 months and who were willing to attend frequent
clinic visits. There was no clear evidence for a similar reduction
in HIV-positive women, but fewer HIV-positive women were
enrolled and there were too few women to stratify the analysis
by adherence. Although the results are consistent with a bene-
ﬁcial effect of acyclovir in both HIV-negative and HIV-positive
women as shedding was lower in the acyclovir arm in
both strata of women, there was weak evidence that the effect
of acyclovir differed in HIV-negative and HIV-positive women.
It is possible that in HIV-positive women in this population,
adherence to this regimen of acyclovir 400 mg twice a day needs
to be very high to suppress HSV shedding adequately.
Most women had HSV detected at least once, but there were
few clinical HSV episodes. Similarly, few genital ulcers were
recorded in the main trial.17 20 Clinical and subclinical recur-
rences decrease in frequency over time,27 28 so most women may
have acquired HSV-2 well before the substudy, and in all cases
women had been infected for at least 18 months. In this setting,
episodic therapy for genital ulcers as currently recommended by
the WHO would have little impact on overall shedding rates.
Women were only seen three times per week, limiting our
ability to describe the duration of shedding episodes. Recent data
from the USA suggest that over half of shedding episodes in
immunocompetent adults last less than 6 h.29 We observed
a similar proportion of one visit episodes.
The study strengths include frequent sampling enabling
detailed description of HSV shedding patterns, the sampling of
multiple genital sites and high rates of follow-up. However, the
following limitations should be considered. First, the number of
women was low in the HIV-positive strata. Second, adherence
estimates corresponded to a 3-month period and therefore may
not always be a good estimate of adherence over the 1-month
duration of this study. Adherence was estimated by pill count at
booked visits and may be overestimated if tablets were discarded
before visits. In addition, it was not possible to tell if participants
were adhering to the 12-hourly treatment schedule. Third, this is
not a true randomised comparison between the placebo and
acyclovir arms because participants were selected 18 months
after randomisation based on other criteria. Finally, the study was
conducted in remote areas. Swabs were stored dry, at 208C for
up to 2 weeks before being transported to a 808C freezer. This
may have led to a slight underestimation of shedding rates, but
was unlikely to have substantially reduced rates of HSV DNA
detection as our previous work showed no decrease in HSV DNA
levels over 1 week in cervicovaginal lavages stored at 208C.30
In summary, shedding was common but shedding patterns
varied greatly by individual. Shedding rates were similar to two
other longitudinal studies in Africa and to studies in non-African
settings. In common with shedding studies in developed coun-
tries, most shedding episodes were asymptomatic. Among HIV-
negative women, HSV shedding rates were lower in the acyclovir
arm, while there was no clear effect in HIV-positive women.
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Key messages
< This is one of the first longitudinal studies to examine HSV
shedding patterns in women in sub-Saharan Africa.
< In this cohort of women enrolled in a HSV suppressive therapy
trial, HSV shedding was common and shedding patterns
varied greatly by individual.
< HSV shedding rates were lower in the acyclovir arm in
HIV-negative women.
< There was no clear effect of acyclovir in HIV-positive women.
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